The European Patent Office approved Bioretec Oy’s hybrid composite material patent application (EP3782657A1), and will grant and publish the patent after the company’s confirmation.
The approved patent concerns magnesium-based reinforced composite material, i.e., a hybrid composite. The patent also includes the usage of the hybrid composite material to manufacture a medical device or a part of such a device.
The patented hybrid composite material will be used in those products of Bioretec’s RemeOs™ product family that require very high load-bearing capacity. Targeted applications include intramedullary nails in the long bones of the upper and lower extremities and implants for spinal fusion. The hybrid composite material biodegrades in the body similarly as the RemeOs magnesium alloy material and is replaced by bone while promoting fracture healing, thus eliminating the need for implant removal surgery.
The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1, and the company will inform about patent approvals in other regions as the application process progress.
The European Patent Office approved Bioretec Oy's hybrid composite material patent application (EP3782657A1), and will grant and publish the patent after the company's confirmation.
The approved patent concerns magnesium-based reinforced composite material, i.e., a hybrid composite. The patent also includes the usage of the hybrid composite...
The European Patent Office approved Bioretec Oy’s hybrid composite material patent application (EP3782657A1), and will grant and publish the patent after the company’s confirmation.
The approved patent concerns magnesium-based reinforced composite material, i.e., a hybrid composite. The patent also includes the usage of the hybrid composite material to manufacture a medical device or a part of such a device.
The patented hybrid composite material will be used in those products of Bioretec’s RemeOs™ product family that require very high load-bearing capacity. Targeted applications include intramedullary nails in the long bones of the upper and lower extremities and implants for spinal fusion. The hybrid composite material biodegrades in the body similarly as the RemeOs magnesium alloy material and is replaced by bone while promoting fracture healing, thus eliminating the need for implant removal surgery.
The patent application process for the hybrid composite material in regions outside of Europe continues based on the international PCT patent application WO2021032882A1, and the company will inform about patent approvals in other regions as the application process progress.
Copy to clipboard 
